An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Intarcia Therapeutics
- 22 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
- 22 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.
- 10 Jun 2017 Biomarkers information updated